iOnctura taps European syndicate for series A to bring two ‘best-in-class’ programs to the clinic

On the strength of its new €15 million ($16.6 million) series A round, iOnctura believes it can have two best-in-class oncology candidates in the clinic within a year.

Created in 2017 by former Merck KGaA (Xetra:MRK) executive Catherine Pickering in partnership with Cancer Research UK to house molecules spun out from both organizations, iOnctura B.V. has attracted an investor syndicate to fund development of two programs it considers its top priorities: a selective PI3Kδ inhibitor and an autotaxin inhibitor...